Logo
x

Search

Subscribe Now

adult

Bristol Myers Squibb's Zeposia (ozanimod) Receives CHMP's Positive Opinion for Adult Patients with Moderately to Severely Active Ulcerative Colitis

Bristol Myers Squibb's Zeposia (ozanimod) Receives CHMP's Positive Opinion for Adult Patients with Moderately to Severely Active U...

  • October 15, 2021
Novartis' Kesimpta (ofatumumab) Receives the EC's Approval for Adult Patients with Relapsing Multiple Sclerosis

Novartis' Kesimpta (ofatumumab) Receives the EC's Approval for Adult Patients with Relapsing Multiple Sclerosis

  • March 30, 2021
BMS and Acceleron's Reblozyl (Luspatercept) Receives Health Canada Approval for Adult Patients With Myelodysplastic Syndromes

BMS and Acceleron's Reblozyl (Luspatercept) Receives Health Canada Approval for Adult Patients With Myelodysplastic Syndromes

  • February 17, 2021
Aurinia Lupkynis (voclosporin) Receives US FDA's Approval to Treat Adult Patients with Active Lupus Nephritis

Aurinia Lupkynis (voclosporin) Receives US FDA's Approval to Treat Adult Patients with Active Lupus Nephritis

  • January 25, 2021
Amgen's Riabni (biosimilar- rituximab) Receives the US FDA's Approval for Multiple Diseases

Amgen's Riabni (biosimilar- rituximab) Receives the US FDA's Approval for Multiple Diseases

  • December 18, 2020
Kite Reports Results of Yescarta in P-II ZUMA-5 Study for Adult Patients with R/R Indolent Non-Hodgkin lymphoma

Kite Reports Results of Yescarta in P-II ZUMA-5 Study for Adult Patients with R/R Indolent Non-Hodgkin lymphoma

  • December 7, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.